Cargando…
Targeting CD22 as a strategy for treating systemic autoimmune diseases
B-cells play an important role in the diagnosis and to some extent the pathogenesis of many autoimmune diseases. Specific B-cell directed antibodies are now gaining an increasing role in the management of these diseases. The first antibody target in this regard was CD20, with the development and int...
Autores principales: | Dörner, Thomas, Goldenberg, David M |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2376077/ https://www.ncbi.nlm.nih.gov/pubmed/18473018 |
Ejemplares similares
-
Epratuzumab targeting of CD22 affects adhesion molecule expression and migration of B-cells in systemic lupus erythematosus
por: Daridon, Capucine, et al.
Publicado: (2010) -
Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus
por: Dörner, Thomas, et al.
Publicado: (2006) -
Correction: Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus
por: Dörner, Thomas, et al.
Publicado: (2008) -
Rationale of anti-CD19 immunotherapy: an option to target autoreactive plasma cells in autoimmunity
por: Mei, Henrik E, et al.
Publicado: (2012) -
Targeting CD22 Reprograms B-Cells and Reverses Autoimmune Diabetes
por: Fiorina, Paolo, et al.
Publicado: (2008)